Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01211262 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
A Phase 1 study, sponsored by Immunocore.
- Completed
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
NCT01211262 is a Phase 1 study that has completed, run by Immunocore. The registered enrollment target is 84 participants.
The verdict
NCT01211262, a Phase 1 study, has completed, sponsored by Immunocore.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
Study Summary
IMCgp100 is a new biological therapy designed for the treatment of melanoma skin cancer. The drug is designed to target melanoma cells and stimulate immune cells to kill them. This trial is designed to establish the level of drug that can be given to a patient that is tolerable. It also designed to establish the best dosing schedule for the drug and to look for signals that the drug is working as intended.
Interventions
- DRUG IMCgp100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2010-09-28 |
| Est. Completion | 2017-02-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01211262
The ClinicalTrials.gov registry entry for NCT01211262 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Immunocore, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IMCgp100 is the first listed.
NCT01211262 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01211262 about?
NCT01211262 is a clinical study titled "Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma". IMCgp100 is a new biological therapy designed for the treatment of melanoma skin cancer. The drug is designed to target melanoma cells and stimulate immune cells to kill them. This trial is designed to establish the level of drug that can be given to a patient that is tolerable. It also designed to ...
What is the current status of trial NCT01211262?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2010-09-28. Estimated completion is 2017-02-16.
What interventions are being tested in trial NCT01211262?
The interventions under investigation include: IMCgp100 (DRUG).
Who is sponsoring clinical trial NCT01211262?
This trial is sponsored by Immunocore, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.